TP53 and small cell lung carcinoma: Nevertheless, SCLC tumors harboring loss-of-function TP53 mutations exhibited a somewhat lower median overall survival in comparison with SCLC tumors expressing a functioning p53 protein (8.0 vs. 8.8 months, hazard ratio (HR) = 1.6 (1.1–2.5), p = 0.03).